id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-320625-ggx33mpt	Lipworth, Brian	Use of inhaled corticosteroids in asthma and coronavirus disease 2019: Keep calm and carry on	2020-07-01		.txt	text/plain	1162	66	46	The novel coronavirus disease 2019 pandemic has inevitably focused attention on whether ICS could predispose to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially in older, male, obese, smokers with comorbidities including chronic lung diseases who are susceptible to severe COVID-19 infection and worse outcomes. In addition, it has been found that in sputum cells from 330 asthma patients, the use of ICS was associated with reduced gene expression of angiotensin converting enzyme 2 and transmembrane serine protease 2, both of which are pivotal membrane bound receptors involved in the host cell entry of SARS-CoV-2. Randomized controlled trials may also be warranted in patients who do not have asthma to confirm whether secondary prevention with ICS including ciclesonide or mometasone can prevent progression of early COVID-19 infection in susceptible older patients with comorbidities. Meanwhile, for patients with asthma, the current guidance is to continue taking their ICS containing controller therapy because it may confer optimal protection against viral infections including SARS-CoV-2 and may also prevent eosinophilic related exacerbations.	./cache/cord-320625-ggx33mpt.txt	./txt/cord-320625-ggx33mpt.txt